CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D014115: Toxemia NIH

(Synonyms: Toxe, Toxemia)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1654 MMR vaccine Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D018746 Systemic Inflammatory Response Syndrome NIH 0.58
D018805 Sepsis NIH 0.45

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0100806 Sepsis HPO 0.45

There is one clinical trial.

Clinical Trials


1 Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation

The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.

NCT04475081 Sepsis Syndrome Biological: MMR vaccine
MeSH:Sepsis Toxemia Systemic Inflammatory Response Syndrome
HPO:Sepsis

Primary Outcomes

Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

Measure: Induction of myeloid-derived suppressor cells (MDSCs)

Time: 14 days post-vaccination

Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

Measure: Induction of MDSCs

Time: 30 days post vaccination

Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

Measure: Induction of MDSCs

Time: 60 days post vaccination

Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

Measure: Induction of MDSCs

Time: 12 months post vaccination

Secondary Outcomes

Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

Measure: COVID-19 infection positive

Time: 14 days post-vaccination

Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

Measure: COVID-19 infection positive

Time: 30 days post-vaccination

Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

Measure: COVID-19 infection positive

Time: 60 days post-vaccination

Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

Measure: COVID-19 infection positive

Time: 12 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 14 days post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 30 days post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 60 days post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 3 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 4 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 5 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 6 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 7 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 8 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 9 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 10 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 11 months post-vaccination

Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

Measure: Health questionnaire

Time: 12 months post-vaccination


HPO Nodes